Please use this identifier to cite or link to this item:
http://hdl.handle.net/10553/130575
| Title: | Transform-1: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, International Phase 3 Study of Navitoclax in Combination with Ruxolitinib Versus Ruxolitinib Plus Placebo in Patients with Untreated Myelofibrosis | Authors: | Pemmaraju, Naveen Mead, Adam J. Somervaille, Tim C. P. McCloskey, James K. Palandri, Francesca Koschmieder, Steffen Lavie, David Leber, Brian Yeh, Su-Peng Gómez Casares, María Teresa Ammatuna, Emanuele Shin, Ho-Jin Kirito, Keita Jourdan, Eric Devos, Timothy Chuah, Hun S. Radinoff, Atanas Bogdanovic, Andrija Moskal, Rastislav Jiang, Qi Chopra, Avijeet S. Papadopoulos, Elektra Potluri, Jalaja Passamonti, Francesco |
UNESCO Clasification: | 32 Ciencias médicas 3209 Farmacología |
Issue Date: | 2023 | Journal: | Blood | Conference: | The 65th ASH Annual Meeting Abstracts | URI: | http://hdl.handle.net/10553/130575 | ISSN: | 0006-4971 | DOI: | 10.1182/blood-2023-173509 | Source: | Blood[ISSN 0006-4971],v. 142 sup. 1, p. 620-624 (Noviembre 2023) |
| Appears in Collections: | Actas de congresos |
Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.